Background Predicated on the mechanism of actions, merging somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents might provide synergistic results for the treating patients with neuroendocrine tumours (NETs). 18 individuals received between 2 and 5 mixtures. Lanreotide was primarily administered in conjunction with everolimus (73 mixtures) or sunitinib (61 mixtures). The likelihood of becoming… Continue reading Background Predicated on the mechanism of actions, merging somatostatin analogues (SSAs)